Outcomes of IVF cycles coupled with PGS by aCGH of embryos from donor and autologous oocytes, transferred after vitrification to women of advanced maternal age

Fedorova, Elena; Shlykova, Svetlana Aleksandrovna; Shunkina, Ksenia V; Zaitceva, Olga G; Лапина, Е. Н.; Yanchuk, Taras V; Kalugina, A. S.

doi:10.1080/09513590.2017.1318274

Cited by 5 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fedorova et al evaluated the use of PGT-A via aCGH in patients with advanced maternal age who utilized either autologous or donor oocytes. 9 They expectedly found that non-PGT-A autologous cycles had higher miscarriage rates than non-PGT-A OD cycles, with the latter group presenting an SABR of 21%. Limitations were that the ages of the donors were not discussed and delivery rates were not available.…”

Section: Discussionmentioning

confidence: 96%

A Comparison of Pregnancy Outcomes in Patients Undergoing Donor Egg Single Embryo Transfers With and Without Preimplantation Genetic Testing

et al. 2019

View full text Add to dashboard Cite

Two of the many milestone developments in the field of assisted reproduction have been oocyte donation and preimplantation genetic testing for aneuploidy (PGT-A). Because it has been demonstrated that even young women produce a meaningful proportion of aneuploid embryos, screening out such abnormalities could potentially increase the efficacy of donor egg (DE) cycles. In this retrospective cohort study, we investigated the effect of PGT-A on DE cycle outcomes, including implantation rate (IR), spontaneous abortion rate (SABR), and ongoing pregnancy/live birth rate. We used fresh and frozen donor cycles not using PGT-A as comparison groups; all cases involved single embryo transfer. Data analysis revealed that PGT-A did not improve pregnancy outcome metrics in DE cycles, although there was a trend toward decreasing the SABR. There was a significant increase in IR with fresh cycles outperforming all frozen cycles. Overall, these results suggest that the benefits of performing PGT-A on embryos derived from young DEs may be limited and that there is an effect of the freezing process on pregnancy outcomes. These findings may provide useful insights into the science and practice of PGT-A across all of its applications.

show abstract

Section: Discussionmentioning

confidence: 96%

A Comparison of Pregnancy Outcomes in Patients Undergoing Donor Egg Single Embryo Transfers With and Without Preimplantation Genetic Testing

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Even young oocyte donors may produce significant rates of chromosomally abnormal embryos. An unexpectantly wide range of chromosomal abnormalities in embryos derived from young oocyte donors (average age, 24-27.8 years) has been reported by several studies (18%-61%) (20)(21)(22)(23)(24)(25)(26).…”

mentioning

confidence: 96%

“…Whether this higher than expected prevalence is related to advanced paternal age of the recipients is still uncertain. Although OD represents a good model to address this question by enabling a control for maternal age, the existing literature regarding the effect of paternal age on embryo aneuploidy in embryos derived from OD is limited, and the specific paternal age effect remains a subject of controversy (19,(26)(27)(28)(29)(30). Moreover, literature on associations between paternal age and specific types of aberrations, including segmental and complex aberrations, in egg donor cycles, is scarce.…”

mentioning

confidence: 99%

Is there a correlation between paternal age and aneuploidy rate? An analysis of 3,118 embryos derived from young egg donors

Dviri

Madjunkova

Koziarz

et al. 2020

Fertility and Sterility

View full text Add to dashboard Cite

Objective: To investigate a possible correlation between chromosomal aberrations and paternal age, analyzing embryos derived from young oocyte donors, with available preimplantation genetic testing for aneuploidy results from day 5/6 trophectoderm biopsy obtained by next-generation sequencing for all 24 chromosomes. Design: Retrospective cohort study. Setting: Canadian fertility centre. Patient(s): A total of 3,118 embryos from 407 male patients, allocated into three paternal age groups: group A, %39 years (n ¼ 203); group B, 40-49 years (n ¼ 161); group C, R50 years (n ¼ 43). Intervention(s): None. Main Outcome Measure(s): The primary outcomes were aneuploidy, euploidy, mosaicism, and blastocyst formation rates. Secondary endpoints were comparison of specific chromosome aneuploidy, segmental and complex (involving two chromosomes þ mosaicism >50%) aneuploidy, and analysis of overall percentage of chromosomal gains and losses within each group. Result(s):The study included 437 in vitro fertilization (IVF) antagonist cycles using 302 oocyte donors in which preimplantation genetic testing for aneuploidy was performed. Overall, 70.04% of embryos were euploid, 13.9% were aneuploid, and 16.06% were mosaic. No significant differences among paternal age groups A, B, and C were found in euploidy rates (69.2%, 70.6%, 71.4%, respectively), aneuploidy rates (14.7%, 12.8%, 13.9%, respectively) or mosaicism rates (16.1%, 16.6%, 13.6%; respectively). The fertilization rate was lower in group C compared with group B (76.35% vs. 80.09%). No difference was found in blastocyst formation rate between the study groups (median 52% [interquartile range, 41%, 67%] vs. 53% [42%, 65%] vs. 52% [42%, 64%], respectively). A generalized linear mixed model regression analysis for embryo ploidy rates found older oocyte donor age to be independently associated with embryo aneuploidy (odds ratio ¼ 1.041; 95% CI, 1.009-1.074). The rate of segmental aneuploidies was significantly higher in the older versus younger paternal age group (36.6% vs. 19.4%). Conclusion(s):No association was found between paternal age and aneuploidy rates in embryos derived from IVF cycles using young oocyte donors, after adjusting for donor, sperm, and IVF cycle characteristics. Advanced paternal age R 50, compared with younger paternal ages, was associated with a lower fertilization rate and increased rate of segmental aberrations. (Fertil Steril Ò 2020;114: 293-300. Ó2020 by American Society for Reproductive Medicine.) El resumen está disponible en Español al final del artículo.

show abstract

“…Theoretically, the transfer of euploid embryos would increase the implantation rate and live birth rate. However, the efficacy of PGT-A in patients with advanced maternal age is still debated (23)(24)(25). Moayeri suggested that PGT-A could be recommended as a screening method for all patients of advanced maternal age.…”

Section: Discussionmentioning

confidence: 99%

“…et al(23) held that the regular use of PGT-A in advanced maternal age should not be recommended. However, Elena et al(24) …”

mentioning

confidence: 97%

Role of aneuploidy screening in preimplantation genetic testing for monogenic diseases in young women

Hou

Song

et al. 2019

Fertility and Sterility

View full text Add to dashboard Cite

Objective: To investigate whether aneuploidy screening in preimplantation genetic testing (PGT) for monogenic diseases improves the ongoing pregnancy/live birth rate of single frozen/thawed embryo transfer (FET) cycles in young women. Design: Retrospective cohort study. Setting: Single university-based fertility center. Patient(s): From January 2016 to December 2017, 569 FET cycles were selected for analysis. The aneuploidy screening (AS) group included 131 FET cycles from 105 oocyte retrieval cycles in 98 patients who underwent PGT for monogenic diseases with aneuploidy screening, and the non-AS group included 438 FET cycles from 280 oocyte retrieval cycles in 266 patients who underwent PGT for monogenic diseases without aneuploidy screening. Intervention(s): The patient population was all under the age of 35 years and underwent PGT for monogenic diseases with and without AS. Main Outcome Measure(s): Ongoing pregnancy/live birth rate, live birth rate, implantation rate, and miscarriage rate. Result(s): Aneuploidy screening significantly improved the ongoing pregnancy/live birth rate (61.22% vs. 43.98%), implantation rate (64.29% vs. 50.38%), and live birth rate (53.06% vs. 36.09%) of young women carrying monogenic diseases in the first FET cycles. When adjusted for the parity, number of previous miscarriages, and percentage of infertility, the likelihood of implantation was 1.874 times higher (95% confidence interval 1.126-3.119), and an ongoing pregnancy/live birth was 2.139 times more likely (95% confidence interval 1.295-3.534). In addition, the miscarriage rate was significantly decreased (3.17% vs. 11.94%). In the cumulative pregnancy outcomes, the cumulative ongoing pregnancy/live birth rate both per transfer and per patient were significantly higher in the AS group (62.24% vs. 50.38% and 79.59% vs. 68.80%), but no difference existed after adjusting for the parity, number of previous miscarriage, and percentage of infertility. Nevertheless, aneuploidy screening reduced the time interval from the first ET to the achievement a pregnancy. Conclusion(s): Aneuploidy screening in PGT significantly improved the ongoing pregnancy/live birth rate of young women carrying monogenic diseases in the first FET cycles. (Fertil Steril Ò 2019;111:928-35. Ó2019 by American Society for Reproductive Medicine.) El resumen está disponible en Español al final del artículo.

show abstract

Outcomes of IVF cycles coupled with PGS by aCGH of embryos from donor and autologous oocytes, transferred after vitrification to women of advanced maternal age

Cited by 5 publications

References 23 publications

A Comparison of Pregnancy Outcomes in Patients Undergoing Donor Egg Single Embryo Transfers With and Without Preimplantation Genetic Testing

A Comparison of Pregnancy Outcomes in Patients Undergoing Donor Egg Single Embryo Transfers With and Without Preimplantation Genetic Testing

Is there a correlation between paternal age and aneuploidy rate? An analysis of 3,118 embryos derived from young egg donors

Role of aneuploidy screening in preimplantation genetic testing for monogenic diseases in young women

Contact Info

Product

Resources

About